Loading the section…

AUTL: financial statements from SEC — TradeAlmanac

AUTL

Autolus Therapeutics plc: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Revenue	26M	21M	21M	9M	0	0
Cost of revenue	25M	29M	24M	18M	0	0
Research and development	21M	28M	27M	27M	40M	37M
Selling, general and administrative	40M	36M	30M	30M	27M	22M
Operating income	−60M	−72M	−61M	−65M	−68M	−59M
Pre-tax income	−71M	−79M	−48M	−68M	−82M	−58M
Income tax	863,000	532,000	397,000	2M	22,000	51,000
Net income	−72M	−79M	−48M	−70M	−82M	−58M
Earnings per share	−0.27	−0.30	−0.18	−0.26	−0.31	−0.22
Earnings per share, diluted	−0.27	−0.30	−0.18	−0.26	−0.31	−0.22
Weighted average shares	266M	266M	266M	266M	266M	266M
Weighted average shares, diluted	266M	266M	266M	266M	266M	266M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	131M	104M	86M	124M	96M	227M	657M	706M
Receivables	28M	24M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	−65M	−76M
Depreciation and amortisation	2M	2M
Capital expenditure	3M	8M
Investing cash flow	96M	−60M
Financing cash flow	−2M	0

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator